---
title: "Infectious Skin Diseases"
order: 3
category: "Dermatology"
---

# Infectious Skin Diseases

## Overview

Infectious skin diseases encompass a broad spectrum of conditions caused by bacteria, viruses, fungi, and parasites. These infections can range from superficial, self-limited conditions to severe, life-threatening systemic diseases. Understanding the clinical presentation, diagnosis, and management of cutaneous infections is essential for appropriate treatment and prevention of complications. This chapter focuses on common bacterial, viral, and fungal skin infections encountered in clinical practice.

### Classification
- **Bacterial**: Impetigo, folliculitis, cellulitis, erysipelas, necrotizing fasciitis
- **Viral**: Herpes simplex, varicella-zoster, warts, molluscum contagiosum
- **Fungal**: Dermatophyte infections, candidiasis, deep fungal infections
- **Parasitic**: Scabies, lice, cutaneous larva migrans

### Epidemiology
- **Prevalence**: Skin infections account for significant morbidity worldwide
- **Risk factors**: Immunosuppression, diabetes, trauma, crowded conditions
- **Geographic variation**: Some infections more common in tropical climates
- **Economic burden**: Substantial healthcare costs and lost productivity

## Bacterial Skin Infections

### Impetigo

#### Definition and Classification
Impetigo is a highly contagious superficial bacterial skin infection primarily affecting children. It is the most common bacterial skin infection in pediatric patients.

**Types:**
- **Non-bullous impetigo**: 70% of cases, honey-crusted lesions
- **Bullous impetigo**: 30% of cases, fluid-filled bullae
- **Ecthyma**: Deep ulcerative form affecting dermis

#### Pathophysiology

**Causative Organisms:**
- **Staphylococcus aureus**: Most common cause currently, including MRSA strains
- **Group A Streptococcus (GAS)**: Historically most common, now less frequent
- **Mixed infection**: Both organisms may be present

**Mechanism:**
- **Non-bullous**: Direct bacterial invasion through breaks in skin
- **Bullous**: Epidermolytic toxins (exfoliatin A and B) cause intraepidermal cleavage
- **Transmission**: Direct contact, autoinoculation, fomites
- **Colonization**: Nasal carriage of S. aureus is risk factor

#### Clinical Presentation

**Non-bullous Impetigo:**
- **Initial lesion**: Small vesicle or pustule on erythematous base
- **Evolution**: Ruptures quickly, forms characteristic honey-colored crust
- **Distribution**: Face (perioral, nares), extremities
- **Satellite lesions**: Spread by autoinoculation
- **Regional lymphadenopathy**: May be present
- **Systemic symptoms**: Usually absent

**Bullous Impetigo:**
- **Initial lesion**: Superficial bulla with clear to cloudy fluid
- **Size**: Variable, can be several centimeters
- **Progression**: Ruptures, leaves collarette of scale with central crusting
- **Distribution**: Trunk, intertriginous areas, face
- **Nikolsky sign**: Negative (unlike SSSS)
- **Age**: More common in neonates and young infants

**Ecthyma:**
- **Lesion**: Punched-out ulcer with overlying crust
- **Depth**: Extends into dermis
- **Location**: Lower extremities most common
- **Healing**: Leaves scar
- **Risk factors**: Poor hygiene, malnutrition, immunosuppression

#### Diagnosis
- **Usually clinical**: Based on characteristic appearance
- **Culture**: If extensive, recurrent, or MRSA suspected
- **ASO titer**: For GAS, if post-streptococcal complications suspected

#### Complications
- **Post-streptococcal glomerulonephritis**: Rare, from nephritogenic strains of GAS
- **Cellulitis**: Extension into deeper tissues
- **Scarring**: From ecthyma
- **Staphylococcal scalded skin syndrome**: In infants with bullous impetigo

#### Treatment

**Topical Therapy (Localized):**
- **Mupirocin 2% ointment**: Three times daily for 5-7 days
- **Retapamulin 1% ointment**: Twice daily for 5 days
- **Preparation**: Remove crusts gently with soap and water
- **Coverage**: Apply to lesions and immediate surrounding area

**Oral Antibiotics (Extensive or Refractory):**
- **Dicloxacillin**: 250-500 mg four times daily for 7 days
- **Cephalexin**: 250-500 mg four times daily for 7 days
- **Cefadroxil**: 1 g daily for 7 days
- **MRSA coverage**: Trimethoprim-sulfamethoxazole, doxycycline, clindamycin if suspected

**Prevention:**
- **Hygiene**: Regular handwashing, keep nails trimmed
- **Wound care**: Clean and cover breaks in skin
- **Decolonization**: Mupirocin to nares if recurrent infections
- **Isolation**: Keep children home from school until lesions crusted or 24 hours after antibiotics

### Folliculitis

#### Definition
Folliculitis is inflammation of the hair follicle caused by infection, physical irritation, or chemical injury.

#### Types and Causes

**Bacterial Folliculitis:**
- **S. aureus**: Most common cause
- **Pseudomonas aeruginosa**: Hot tub folliculitis
- **Gram-negative**: Prolonged antibiotic use for acne

**Other Forms:**
- **Pityrosporum folliculitis**: Malassezia yeast overgrowth
- **Eosinophilic folliculitis**: HIV-associated
- **Mechanical folliculitis**: Friction, occlusion
- **Demodex folliculitis**: Mite overgrowth

#### Clinical Presentation

**Superficial Folliculitis:**
- **Lesions**: Small pustules with central hair
- **Distribution**: Hair-bearing areas (face, scalp, trunk, extremities)
- **Symptoms**: Pruritus, mild tenderness
- **Resolution**: Self-limited in many cases

**Deep Folliculitis (Furuncle/Abscess):**
- **Furuncle**: Painful, deep follicular abscess
- **Carbuncle**: Coalescence of multiple furuncles
- **Fluctuance**: Central area becomes fluctuant
- **Drainage**: May spontaneously drain purulent material
- **Scarring**: May occur

**Hot Tub Folliculitis:**
- **Timing**: 8-48 hours after hot tub or pool exposure
- **Distribution**: Trunk, buttocks, areas covered by swimsuit
- **Appearance**: Pruritic papules and pustules
- **Self-limited**: Resolves in 7-10 days
- **Prevention**: Proper pool chlorination

#### Diagnosis
- **Clinical**: Usually sufficient
- **Culture**: If persistent, recurrent, or immunocompromised
- **KOH prep**: To rule out fungal infection

#### Treatment

**Mild Cases:**
- **Hygiene**: Gentle cleansing, avoid occlusion
- **Antiseptic washes**: Benzoyl peroxide, chlorhexidine
- **Warm compresses**: Promote drainage
- **Topical antibiotics**: Mupirocin for limited involvement

**Moderate to Severe:**
- **Oral antibiotics**: Dicloxacillin, cephalexin for 7-10 days
- **MRSA coverage**: If endemic or culture-positive
- **Incision and drainage**: For furuncles and abscesses

**Recurrent Folliculitis:**
- **Decolonization**: Mupirocin to nares twice daily for 5 days
- **Bleach baths**: 1/4 cup in full tub, twice weekly
- **Culture**: Patient and close contacts
- **Environmental**: Clean towels, clothing, sheets

### Cellulitis and Erysipelas

#### Definitions
- **Cellulitis**: Acute infection of dermis and subcutaneous tissue
- **Erysipelas**: Superficial dermis and lymphatics, well-demarcated border

#### Pathophysiology

**Causative Organisms:**
- **Group A Streptococcus**: Most common for erysipelas
- **S. aureus**: Common cause of cellulitis, including MRSA
- **Other streptococci**: Group B, C, G
- **Special circumstances**:
  - Water exposure: Aeromonas, Vibrio
  - Animal bites: Pasteurella, Capnocytophaga
  - Neutropenic: Gram-negative bacilli, Pseudomonas

**Entry Points:**
- **Trauma**: Cuts, abrasions, puncture wounds
- **Fissures**: Tinea pedis, eczema, xerosis
- **Ulcers**: Venous, diabetic, pressure ulcers
- **Surgical wounds**: Postoperative infection
- **No apparent portal**: May be present

**Risk Factors:**
- **Lymphedema**: Impaired lymphatic drainage
- **Venous insufficiency**: Edema, stasis
- **Obesity**: Intertriginous maceration
- **Diabetes**: Impaired immunity, peripheral neuropathy
- **Immunosuppression**: Medications, HIV, malignancy
- **Prior cellulitis**: Damaged lymphatics increase recurrence risk

#### Clinical Presentation

**Cellulitis:**
- **Appearance**: Erythema, warmth, swelling, tenderness
- **Border**: Poorly defined, gradual transition to normal skin
- **Distribution**: Lower extremity most common (70-80%)
- **Systemic symptoms**: Fever, chills, malaise
- **Lymphangitis**: Red streaks toward regional lymph nodes
- **Lymphadenopathy**: Regional nodes enlarged and tender

**Erysipelas:**
- **Appearance**: Bright red, indurated plaque
- **Border**: Sharp, raised, well-demarcated
- **Surface**: Shiny, peau d'orange appearance
- **Location**: Face (butterfly distribution) or lower legs
- **Vesicles/bullae**: May develop on surface
- **Systemic symptoms**: Often more prominent than cellulitis

**Severity Assessment:**
- **Mild**: No systemic symptoms, able to take oral medications
- **Moderate**: Systemic symptoms, oral intake adequate
- **Severe**: Hemodynamic instability, immunocompromised, failed outpatient therapy

#### Differential Diagnosis
- **Stasis dermatitis**: Bilateral, chronic, pruritic, hemosiderin deposition
- **Contact dermatitis**: Pruritic, vesicular, exposure history
- **Deep vein thrombosis**: Unilateral, calf tenderness, Homan's sign
- **Necrotizing fasciitis**: Severe pain, crepitus, rapid progression, bullae, skin necrosis
- **Gout**: Joint involvement, monoarticular, crystal identification

#### Diagnosis
- **Clinical**: Diagnosis is primarily clinical
- **Blood cultures**: Positive in <5%, obtain if systemic signs
- **Wound culture**: Only if purulent drainage present
- **Imaging**: Not routinely needed
  - Ultrasound: Rule out DVT or abscess
  - CT/MRI: If necrotizing fasciitis suspected

#### Complications
- **Abscess formation**: May require drainage
- **Necrotizing fasciitis**: Surgical emergency
- **Bacteremia/sepsis**: Especially in immunocompromised
- **Post-streptococcal glomerulonephritis**: Rare
- **Lymphedema**: Chronic, from lymphatic damage
- **Recurrent cellulitis**: 8-20% experience recurrence

#### Treatment

**Outpatient (Mild to Moderate):**
- **Empiric coverage**: Streptococcus and S. aureus
- **Options**:
  - Cephalexin 500 mg four times daily
  - Dicloxacillin 500 mg four times daily
  - Cefadroxil 1 g daily or divided twice daily
- **MRSA risk factors**: Purulent drainage, prior MRSA, injection drug use
  - Add: Trimethoprim-sulfamethoxazole or doxycycline
  - Or: Clindamycin monotherapy
- **Duration**: 5-10 days, typically 7 days
- **Adjunctive**: Elevation, compression, pain management

**Inpatient (Severe or Complications):**
- **IV antibiotics**:
  - Cefazolin 1-2 g IV every 8 hours
  - Nafcillin or oxacillin 2 g IV every 4-6 hours
- **MRSA coverage**:
  - Vancomycin 15-20 mg/kg IV every 8-12 hours
  - Daptomycin 4 mg/kg IV daily (not on face/lungs)
  - Linezolid 600 mg IV/PO twice daily
- **Transition**: Switch to oral when improving and afebrile 24 hours
- **Total duration**: 10-14 days typically

**Recurrent Cellulitis Prevention:**
- **Address predisposing factors**: Treat tinea pedis, moisturize, manage edema
- **Prophylaxis**: Penicillin VK 250 mg twice daily or erythromycin 250 mg twice daily
- **Duration**: At least 12 months if ≥2 episodes per year
- **Compression**: For lymphedema or venous insufficiency

## Viral Skin Infections

### Herpes Simplex Virus (HSV)

#### Virology and Epidemiology
- **Types**: HSV-1 (typically orofacial), HSV-2 (typically genital)
- **Epidemiology**: HSV-1 seroprevalence 50-90%, HSV-2 15-20% in US
- **Transmission**: Direct contact with lesions or asymptomatic viral shedding
- **Latency**: Establishes latency in sensory ganglia (trigeminal for HSV-1, sacral for HSV-2)

#### Clinical Presentations

**Primary HSV Infection:**
- **Gingivostomatitis (HSV-1)**: Most common primary manifestation in children
  - Widespread oral vesicles and ulcers
  - Painful, interferes with eating and drinking
  - Fever, irritability, lymphadenopathy
  - Duration: 10-14 days
- **Primary genital herpes (HSV-2 or HSV-1)**:
  - Grouped vesicles on genitals, painful
  - Bilateral distribution common
  - Dysuria, urinary retention may occur
  - Systemic symptoms: Fever, myalgias, headache
  - Duration: 2-3 weeks

**Recurrent HSV:**
- **Prodrome**: Tingling, burning, itching 24-48 hours before lesions
- **Lesions**: Grouped vesicles on erythematous base
- **Location**: Same dermatome, typically at mucocutaneous junction
- **Duration**: 7-10 days
- **Frequency**: Variable, averages 2-3 per year
- **Triggers**: UV exposure, stress, immunosuppression, trauma, menses

**Orofacial HSV:**
- **Herpes labialis**: "Cold sore" on lip
- **Location**: Vermillion border most common
- **Evolution**: Vesicles → pustules → crusts
- **Self-limited**: Resolves in 7-10 days

**Herpes Whitlow:**
- **Location**: Finger (often healthcare workers, thumb-sucking children)
- **Presentation**: Painful, swollen digit with vesicles
- **Differential**: Bacterial paronychia (but incision contraindicated)

**Eczema Herpeticum:**
- **Population**: Patients with atopic dermatitis
- **Presentation**: Widespread vesiculopustular eruption, punched-out erosions
- **Systemic**: Fever, malaise
- **Complications**: Bacteremia, keratitis, meningitis
- **Treatment**: IV acyclovir if severe

**Neonatal HSV:**
- **Transmission**: Perinatal (during delivery), rarely congenital
- **Risk**: Highest with primary maternal infection at delivery
- **Forms**: Localized (skin/eye/mouth), CNS, disseminated
- **Mortality**: High without treatment
- **Treatment**: IV acyclovir

#### Diagnosis
- **Clinical**: Often sufficient for typical cases
- **Tzanck smear**: Multinucleated giant cells (cannot distinguish HSV from VZV)
- **PCR**: Gold standard, rapid, sensitive and specific
- **Viral culture**: Definitive but slower, sensitivity decreases as lesions heal
- **DFA**: Direct fluorescent antibody, rapid but less sensitive than PCR
- **Serology**: IgG type-specific antibodies, for diagnosis of infection but not acute disease

#### Treatment

**Acute Episodes:**

*Primary infection (oral):*
- **Acyclovir**: 400 mg PO five times daily or 200 mg five times daily for 7-10 days
- **Valacyclovir**: 1 g PO twice daily for 7-10 days
- **Famciclovir**: 250 mg PO three times daily for 7-10 days

*Recurrent episodes:*
- **Acyclovir**: 400 mg PO three times daily for 5 days
- **Valacyclovir**: 500 mg PO twice daily for 3 days or 2 g twice daily for 1 day
- **Famciclovir**: 1000 mg PO twice daily for 1 day or 500 mg once, then 250 mg twice daily for 2 days

*Severe or immunocompromised:*
- **IV acyclovir**: 5-10 mg/kg every 8 hours

**Suppressive Therapy (for frequent recurrences):**
- **Indications**: ≥6 episodes per year, severe recurrences, immunocompromised
- **Acyclovir**: 400 mg PO twice daily
- **Valacyclovir**: 500-1000 mg PO daily
- **Famciclovir**: 250 mg PO twice daily
- **Duration**: Reevaluate annually

**Topical Therapy:**
- **Acyclovir cream**: Limited efficacy, shortens episode by ~0.5 days
- **Penciclovir cream**: Similar limited efficacy
- **Not recommended**: As monotherapy for immunocompetent patients

### Varicella-Zoster Virus (VZV)

#### Varicella (Chickenpox)

**Epidemiology:**
- **Pre-vaccine**: >90% acquired by adulthood
- **Post-vaccine**: Significant decrease in incidence
- **Transmission**: Respiratory droplets, direct contact with lesions
- **Contagious period**: 1-2 days before rash until all lesions crusted

**Clinical Presentation:**
- **Prodrome**: Low-grade fever, malaise 1-2 days before rash
- **Rash**: Begins on face/trunk, spreads centrifugally
- **Morphology**: "Dew drop on a rose petal" – vesicle on erythematous base
- **Evolution**: Macule → papule → vesicle → crust
- **Stages**: Lesions in different stages simultaneously (hallmark)
- **Distribution**: Generalized, including scalp and mucous membranes
- **Pruritus**: Often intense

**Complications:**
- **Bacterial superinfection**: S. aureus, GAS (most common complication)
- **Pneumonia**: More severe in adults, immunocompromised, pregnant women
- **Encephalitis/cerebellitis**: Rare, ataxia in children usually benign
- **Reye syndrome**: Associated with aspirin use
- **Hemorrhagic varicella**: Immunocompromised
- **Congenital varicella**: Maternal infection in first 20 weeks

**Diagnosis:**
- **Clinical**: Usually sufficient (characteristic rash, exposure)
- **PCR**: From vesicle fluid if confirmation needed
- **DFA**: Direct fluorescent antibody
- **Serology**: IgM for acute, IgG for immunity

**Treatment:**
- **Healthy children**: Supportive care (antipruritic, antipyretic)
- **Antivirals indicated for**:
  - Adolescents and adults
  - Immunocompromised
  - Chronic skin/lung disease
  - Long-term salicylate therapy
  - Pregnant women
- **Acyclovir**: 20 mg/kg (max 800 mg) four times daily for 5 days (oral)
- **IV acyclovir**: For severe cases or immunocompromised (10 mg/kg every 8 hours)

**Prevention:**
- **Vaccination**: Live attenuated vaccine, 2 doses
  - Dose 1: 12-15 months
  - Dose 2: 4-6 years
  - Efficacy: >90% prevention of severe disease
- **Post-exposure prophylaxis**:
  - VariZIG (varicella-zoster immune globulin): For high-risk exposed individuals
  - Vaccination within 3-5 days: May prevent or modify disease

#### Herpes Zoster (Shingles)

**Pathophysiology:**
- **Reactivation**: VZV reactivates from dorsal root ganglion
- **Triggers**: Aging, immunosuppression, stress, trauma
- **Incidence**: 1 in 3 lifetime risk, increases with age
- **Immunity**: Prior varicella (clinical or subclinical) required

**Clinical Presentation:**
- **Prodrome**: Pain, burning, tingling in dermatomal distribution 1-5 days before rash
- **Rash**: Grouped vesicles on erythematous base
- **Distribution**: Unilateral, dermatomal (does not cross midline)
- **Most common**: Thoracic (50%), then cranial (V1), lumbar, sacral
- **Evolution**: Vesicles → pustules → crusts over 7-10 days
- **Resolution**: Complete healing in 2-4 weeks
- **Pain**: Can be severe, often out of proportion to appearance

**Variants:**
- **Ophthalmic zoster (V1 distribution)**: Ophthalmology emergency if eye involved
- **Hutchinson sign**: Vesicles on tip of nose, high risk of ocular involvement
- **Ramsay Hunt syndrome**: Herpes zoster oticus (CN VII, VIII)
  - Facial paralysis, ear pain, vesicles in ear canal
  - Hearing loss, vertigo
- **Disseminated zoster**: ≥20 lesions outside primary and adjacent dermatomes
  - Suggests immunocompromise
- **Zoster sine herpete**: Dermatomal pain without rash

**Complications:**
- **Postherpetic neuralgia (PHN)**: Most common complication
  - Pain persisting >90 days after rash onset
  - Incidence increases with age (>50% over age 60)
  - Can be severe and debilitating
- **Ophthalmic complications**: Keratitis, uveitis, glaucoma, vision loss
- **Ramsay Hunt syndrome**: May have incomplete recovery
- **Motor weakness**: Rare, can occur in affected myotome
- **Bacterial superinfection**: S. aureus, GAS
- **Meningitis/encephalitis**: Rare
- **Dissemination**: In immunocompromised (visceral organ involvement)

**Diagnosis:**
- **Clinical**: Characteristic dermatomal rash usually diagnostic
- **PCR**: From vesicle fluid if confirmation needed
- **DFA**: Direct fluorescent antibody
- **Tzanck smear**: Less specific

**Treatment:**

*Antiviral therapy:*
**Indications**: All patients, especially if:
- Age >50
- Moderate to severe pain or rash
- Immunocompromised
- Cranial nerve involvement

**Regimens (start within 72 hours of rash onset):**
- **Valacyclovir**: 1 g PO three times daily for 7 days (preferred)
- **Famciclovir**: 500 mg PO three times daily for 7 days
- **Acyclovir**: 800 mg PO five times daily for 7 days

**Severe disease or immunocompromised:**
- **IV acyclovir**: 10 mg/kg every 8 hours for 7-10 days

*Pain management:*
- **Acute phase**:
  - Acetaminophen, NSAIDs
  - Opioids if severe
  - Gabapentin or pregabalin
  - Topical lidocaine
- **PHN**:
  - Gabapentin: 300-3600 mg daily (divided three times daily)
  - Pregabalin: 150-600 mg daily (divided twice or three times daily)
  - Tricyclic antidepressants: Nortriptyline 25-100 mg at bedtime
  - Topical: Lidocaine 5% patch, capsaicin 8% patch
  - Opioids: For refractory cases

*Corticosteroids:*
- **Controversial**: May reduce acute pain but no effect on PHN
- **Not routinely recommended**: Especially in immunocompromised

**Prevention:**
- **Recombinant zoster vaccine (Shingrix)**: Preferred, 2 doses 2-6 months apart
  - Recommended: Age ≥50
  - Efficacy: >90% prevention, sustained over years
  - Give even if prior zoster or live vaccine
- **Live attenuated vaccine (Zostavax)**: No longer preferred
  - Single dose
  - Efficacy: ~50% prevention, wanes over time

### Human Papillomavirus (Warts)

#### Types and Locations
- **Common warts (verrucae vulgaris)**: HPV 1, 2, 4 – hands, fingers
- **Plantar warts**: HPV 1, 2, 4 – soles of feet
- **Flat warts (verrucae planae)**: HPV 3, 10 – face, dorsal hands
- **Filiform warts**: Face, neck
- **Genital warts (condyloma acuminata)**: HPV 6, 11 (low-risk)
- **Anogenital dysplasia/cancer**: HPV 16, 18, 31, 33 (high-risk)

#### Pathophysiology
- **Transmission**: Direct skin-to-skin contact, fomites
- **Entry**: Through microabrasions in skin
- **Incubation**: 1-12 months (average 2-3 months)
- **Proliferation**: Viral DNA induces epithelial proliferation
- **Immunity**: Most resolve spontaneously via cell-mediated immunity

#### Clinical Presentation

**Common Warts:**
- **Appearance**: Flesh-colored, hyperkeratotic papules
- **Surface**: Rough, "cauliflower-like"
- **Black dots**: Thrombosed capillaries (distinguish from callus)
- **Location**: Hands, periungual areas
- **Koebner phenomenon**: May develop along scratch lines

**Plantar Warts:**
- **Appearance**: Thick, hyperkeratotic, painful
- **Location**: Weight-bearing areas of feet
- **Disruption of skin lines**: Skin lines do not cross lesion
- **Mosaic warts**: Confluent cluster
- **Pain**: With direct pressure (vs callus with pinching)

**Flat Warts:**
- **Appearance**: Smooth, flat-topped, skin-colored to pink papules
- **Size**: 1-5 mm
- **Number**: Multiple, may be hundreds
- **Distribution**: Face, dorsal hands, shins
- **Linear arrangement**: Koebner phenomenon common

**Filiform Warts:**
- **Appearance**: Finger-like projections
- **Location**: Face, especially around mouth, nose, eyes, beard area
- **Growth**: Rapid

#### Diagnosis
- **Clinical**: Usually sufficient
- **Paring**: Reveals pinpoint bleeding (thrombosed capillaries)
- **Dermoscopy**: Disruption of dermatoglyphics, thrombosed capillaries
- **Biopsy**: Rarely needed, shows koilocytes, papillomatosis, hyperkeratosis

#### Treatment

**Expectant Management:**
- **Spontaneous resolution**: 65% within 2 years
- **Children**: Higher spontaneous resolution rate
- **Consider**: If asymptomatic, not interfering with function

**Destructive Methods:**

*Salicylic acid:*
- **Mechanism**: Keratolytic
- **Concentration**: 17-40%
- **Application**: Daily after paring, cover with tape
- **Duration**: Several weeks to months
- **Efficacy**: 50-70% clearance

*Cryotherapy:*
- **Agent**: Liquid nitrogen
- **Technique**: Freeze for 10-30 seconds, allow thaw, may repeat
- **Frequency**: Every 2-3 weeks
- **Pain**: Can be significant
- **Side effects**: Blistering, hypopigmentation, scarring
- **Efficacy**: 50-70% after 3-4 treatments

*Cantharidin:*
- **Mechanism**: Blister-inducing agent
- **Application**: Apply to wart, cover, wash off in 4-6 hours
- **Blister**: Forms over 24-48 hours
- **Efficacy**: Moderate, may require repeat treatments

*Electrodesiccation and curettage:*
- **Indications**: Recalcitrant warts
- **Procedure**: Local anesthesia, burn and scrape
- **Risks**: Pain, scarring
- **Efficacy**: High but invasive

*Laser therapy:*
- **Pulsed dye laser**: Targets blood vessels
- **CO2 laser**: Ablative
- **Indications**: Refractory warts
- **Efficacy**: Variable, risk of scarring

**Immunomodulatory:**

*Topical imiquimod:*
- **Mechanism**: Immune response modifier (TLR7 agonist)
- **Use**: Off-label for cutaneous warts, FDA-approved for genital
- **Application**: 3-5 times weekly until clear
- **Side effects**: Irritation, erythema

*Intralesional immunotherapy:*
- **Candida antigen injection**: Stimulates immune response
- **Mechanism**: Delayed-type hypersensitivity, distant wart clearance
- **Efficacy**: 60-80% in studies
- **Procedure**: Every 3 weeks until clear

**Other Therapies:**
- **Topical retinoids**: Limited efficacy
- **Cimetidine**: Theoretical immune stimulation, poor evidence
- **Zinc sulfate**: Oral, variable results
- **Duct tape occlusion**: Controversial, studies conflicting

### Molluscum Contagiosum

#### Virology and Epidemiology
- **Virus**: Poxvirus (double-stranded DNA)
- **Transmission**: Direct skin contact, fomites, autoinoculation
- **Populations**: Children most common, sexually active adults (genital), immunocompromised
- **Incubation**: 2-7 weeks

#### Clinical Presentation
- **Lesions**: Flesh-colored, dome-shaped, umbilicated papules
- **Size**: 2-5 mm typically, can be larger in immunocompromised
- **Number**: Few to hundreds
- **Distribution**:
  - Children: Trunk, extremities, face
  - Adults: Genital area if sexually transmitted
  - Immunocompromised: Face, widespread
- **Pruritus**: May be present, leads to autoinoculation
- **Molluscum dermatitis**: Eczematous reaction around lesions

#### Diagnosis
- **Clinical**: Characteristic appearance usually sufficient
- **Expressed material**: Cheesy, white core (molluscum bodies)
- **Histology**: Large intracytoplasmic inclusion bodies (Henderson-Patterson bodies)

#### Natural History
- **Immunocompetent**: Self-limited, resolve over 6-12 months (range 2 months - 4 years)
- **Treatment decision**: Balance spontaneous resolution vs cosmetic/transmission concerns
- **HIV patients**: May be extensive and persistent

#### Treatment

**Expectant management:**
- **Option**: For immunocompetent children if not bothersome
- **Reasoning**: Spontaneous resolution, treatments can be painful
- **Counseling**: Avoid scratching, sharing towels

**Physical destruction:**
- **Curettage**: Scrape off with curette
  - Can use topical anesthetic (EMLA) beforehand
  - Risk: Pain, scarring
- **Cryotherapy**: Freeze lesions
  - Risk: Pain, hypopigmentation
- **Cantharidin**: Blister-inducing agent
  - Less painful than cryotherapy

**Topical therapies:**
- **Imiquimod 5% cream**: 3 times weekly
- **Tretinoin cream**: May cause irritation but stimulate immune response
- **Cimetidine**: Oral, limited evidence
- **Podophyllotoxin**: For genital lesions

**Immunocompromised:**
- **Improve immune status**: ART for HIV patients
- **May require more aggressive therapy**: Multiple modalities

## Fungal Skin Infections

### Dermatophyte Infections (Tinea)

#### Organisms
- **Trichophyton**: Most common (T. rubrum, T. mentagrophytes, T. tonsurans)
- **Microsporum**: Less common (M. canis from animals)
- **Epidermophyton**: E. floccosum

#### Types by Location

**Tinea Pedis (Athlete's Foot):**
- **Most common**: Dermatophyte infection
- **Presentation**:
  - Interdigital: Maceration, fissuring between toes (3rd-4th, 4th-5th web spaces)
  - Moccasin type: Diffuse scaling of plantar surface and sides
  - Inflammatory/vesicular: Vesicles, pustules, bullae
- **Symptoms**: Pruritus, burning, odor
- **Complications**: Secondary bacterial infection, id reaction

**Tinea Cruris (Jock Itch):**
- **Location**: Groin, inner thighs, buttocks
- **Appearance**: Erythematous patches with advancing scaly border
- **Sparing**: Scrotum usually spared (vs candidiasis)
- **More common**: Men, athletes, obesity
- **Bilateral**: Usually

**Tinea Corporis (Ringworm):**
- **Appearance**: Annular erythematous patch/plaque with raised, scaly border
- **Central clearing**: Classic "ringworm" appearance
- **Size**: Variable, can enlarge over time
- **Number**: Single or multiple
- **Transmission**: Person-to-person, pets (M. canis), fomites

**Tinea Capitis (Scalp Ringworm):**
- **Age**: Primarily children (peak 3-7 years)
- **Types**:
  - Scaling: Resembles seborrheic dermatitis or dandruff
  - Black dot: Broken hairs at scalp surface
  - Kerion: Boggy, tender, purulent scalp mass (severe inflammatory response)
- **Organisms**: T. tonsurans (most common in US), M. canis
- **Complications**: Scarring alopecia (especially from kerion)

**Tinea Faciei:**
- **Location**: Face
- **Appearance**: Can be subtle, erythematous patches with fine scale
- **Misdiagnosis**: Often treated as eczema or rosacea initially
- **Border**: May be less distinct than tinea corporis

**Tinea Barbae:**
- **Location**: Beard area
- **Appearance**: Inflammatory folliculitis, kerion-like masses
- **Differential**: Bacterial folliculitis
- **Deep**: May involve deep follicles

**Tinea Unguium (Onychomycosis):**
- **Prevalence**: 10% of population, increases with age
- **Types**:
  - Distal lateral subungual: Most common, yellow discoloration, onycholysis
  - Proximal subungual: White discoloration from cuticle
  - Superficial white: Chalky white patches on nail surface
  - Endonyx: Nail plate invasion without subungual debris
  - Candidal: Paronychia and nail involvement
- **Symptoms**: Usually asymptomatic, cosmetic concern
- **Diagnosis**: KOH or culture before treatment (confirm fungal)

**Tinea Manuum:**
- **Presentation**: Often one hand (two feet, one hand)
- **Appearance**: Dry, scaly palmar surface
- **Pattern**: Hyperkeratosis in creases
- **Misdiagnosis**: Often thought to be hand dermatitis

#### Diagnosis
- **KOH preparation**: Scrape scale from active border, add 10-20% KOH, look for hyphae
- **Culture**: If KOH negative but high suspicion, or identify species
- **Dermoscopy**: Can help identify tinea (scales outside follicles)
- **Wood's lamp**: Some Microsporum species fluoresce (not Trichophyton)
- **Biopsy**: Rarely needed, PAS stain highlights fungal elements

#### Treatment

**Topical Therapy (Localized Tinea Pedis, Cruris, Corporis):**
- **Azoles**: Clotrimazole, miconazole, ketoconazole, econazole
  - Application: Once to twice daily for 2-4 weeks
  - Continue 1 week after clinical clearance
- **Allylamines**: Terbinafine, naftifine
  - More fungicidal than azoles
  - Shorter duration possible (1-2 weeks)
- **Ciclopirox**: Broad-spectrum antifungal
  - Twice daily for 2-4 weeks

**Systemic Therapy (Extensive, Tinea Capitis, Onychomycosis):**

*Tinea Capitis (requires systemic):*
- **Griseofulvin**:
  - Microsize: 20-25 mg/kg/day for 6-12 weeks
  - Ultramicrosize: 10-15 mg/kg/day for 6-12 weeks
  - Take with fatty meal for absorption
- **Terbinafine**:
  - <20 kg: 62.5 mg daily
  - 20-40 kg: 125 mg daily
  - >40 kg: 250 mg daily
  - Duration: 4-6 weeks
- **Fluconazole**: Alternative, 6 mg/kg weekly for 12 weeks
- **Adjunctive**: Antifungal shampoo (ketoconazole 2%) twice weekly

*Onychomycosis:*
- **Terbinafine**: 250 mg daily
  - Fingernails: 6 weeks
  - Toenails: 12 weeks
  - Most effective oral agent
- **Itraconazole**:
  - Continuous: 200 mg daily for 12 weeks
  - Pulse: 200 mg twice daily for 1 week/month, 2-3 pulses
- **Fluconazole**: 150-300 mg weekly for 12-16 weeks (toes)
- **Monitoring**: Baseline LFTs, repeat if treatment >6 weeks
- **Topical options**: Ciclopirox 8% nail lacquer, efinaconazole, tavaborole
  - Less effective than oral but safer
  - Daily application for 48 weeks

*Extensive Tinea Corporis/Pedis:*
- **Terbinafine**: 250 mg daily for 2-4 weeks
- **Itraconazole**: 200 mg daily for 1-2 weeks
- **Fluconazole**: 150-200 mg weekly for 2-4 weeks

### Candidiasis

#### Organism
- **Candida albicans**: Most common species (70-80%)
- **Non-albicans**: C. glabrata, C. tropicalis, C. parapsilosis (increasing)

#### Risk Factors
- **Moisture**: Occlusion, hyperhidrosis
- **Diabetes**: Hyperglycemia promotes growth
- **Antibiotics**: Disrupt normal flora
- **Immunosuppression**: HIV, chemotherapy, corticosteroids
- **Obesity**: Intertriginous areas
- **Dentures**: Oral candidiasis
- **Pregnancy**: Hormonal changes

#### Clinical Presentations

**Cutaneous Candidiasis:**
- **Intertriginous**: Bright red patches with satellite pustules
- **Location**: Axillae, groin, inframammary, intergluteal, interdigital
- **Borders**: Irregular with satellite lesions (key feature)
- **Symptoms**: Pruritus, burning
- **Perianal**: In infants (diaper candidiasis) and diabetics

**Oral Candidiasis (Thrush):**
- **Pseudomembranous**: White plaques on tongue, buccal mucosa (removable, leave erythema)
- **Erythematous**: Smooth, red patches on tongue or palate
- **Angular cheilitis**: Fissures at mouth corners
- **Risk factors**: Inhaled corticosteroids, dentures, immunosuppression

**Vulvovaginal Candidiasis:**
- **Symptoms**: Pruritus, burning, thick white discharge ("cottage cheese")
- **Examination**: Erythema, edema, white plaques on vaginal walls
- **Vulvar involvement**: Erythema, satellite lesions
- **Recurrent**: ≥4 episodes per year

**Chronic Mucocutaneous Candidiasis:**
- **Definition**: Persistent or recurrent candida infections of skin, nails, mucous membranes
- **Cause**: Primary immunodeficiency affecting T-cell function
- **Presentation**: Chronic oral thrush, nail dystrophy, hyperkeratotic skin lesions

**Candidal Paronychia:**
- **Chronic**: Occupational exposure to water (bartenders, dishwashers)
- **Presentation**: Painful, swollen nail fold, loss of cuticle
- **Drainage**: Purulent material may be expressed
- **Nail changes**: Onycholysis, discoloration, transverse ridges

#### Diagnosis
- **Clinical**: Often sufficient with characteristic satellite lesions
- **KOH preparation**: Pseudohyphae and budding yeast
- **Culture**: On Sabouraud agar if needed, identify species
- **Vaginal**: Wet mount shows yeast and pseudohyphae, culture

#### Treatment

**Topical (Cutaneous, Oral):**
- **Azoles**: Clotrimazole, miconazole, ketoconazole
  - Application: Twice daily until clear, then 1-2 weeks beyond
- **Nystatin**: Cream, powder for intertriginous areas
  - Less effective than azoles
- **Amphotericin B**: Lozenges for oral (suck four times daily)
- **Clotrimazole troches**: 10 mg five times daily for 7-14 days
- **Adjunctive**: Keep area dry, absorbent powder

**Systemic (Oral, Esophageal, Recurrent):**
- **Fluconazole**:
  - Vaginal: 150 mg single dose
  - Oral: 100-200 mg daily for 7-14 days
  - Esophageal: 200-400 mg daily for 14-21 days
  - Recurrent VVC: Weekly 150 mg for 6 months
- **Itraconazole**: 200 mg daily (alternatives to fluconazole)
- **Posaconazole**: For refractory cases

**Preventive Measures:**
- **Keep areas dry**: Frequent diaper changes, dry intertriginous areas
- **Barrier**: Zinc oxide, petroleum jelly
- **Avoid irritants**: Perfumed products, harsh soaps
- **Control diabetes**: Optimize glucose control
- **Probiotic**: For recurrent vaginal candidiasis (Lactobacillus)

## Key Points

- Impetigo is highly contagious, presenting with honey-colored crusts (non-bullous) or bullae (bullous type), treated with topical or oral antibiotics
- Cellulitis and erysipelas require clinical diagnosis; empiric antibiotic coverage should include streptococci and S. aureus, with consideration of MRSA risk factors
- Herpes simplex establishes latency and can recur; antiviral therapy is most effective when started early, with suppressive therapy indicated for frequent recurrences
- Herpes zoster presents with dermatomal vesicular rash often preceded by pain; early antiviral treatment reduces severity and postherpetic neuralgia risk
- Warts are caused by HPV and often resolve spontaneously; treatment options include destructive methods and immunomodulatory therapies
- Dermatophyte infections diagnosed by KOH preparation; topical therapy sufficient for most cutaneous infections, but systemic required for tinea capitis and onychomycosis
- Candidiasis presents with erythematous patches and characteristic satellite lesions in moist areas; treatment includes topical antifungals and addressing predisposing factors
- Prevention of infectious skin diseases requires attention to hygiene, barrier integrity, and management of predisposing conditions
- Immunocompromised patients may present with atypical, severe, or disseminated infections requiring more aggressive therapy
- Early recognition and treatment of skin infections prevents complications including scarring, systemic spread, and post-infectious sequelae

## References

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update. Clin Infect Dis. 2014;59(2):147-159.
2. James WD, Elston DM, Treat JR, Rosenbach MA, Neuhaus IM. Andrews' Diseases of the Skin: Clinical Dermatology. 13th ed. Philadelphia: Elsevier; 2019.
3. Gupta AK, Venkataraman M, Renaud HJ, et al. The increasing problem of treatment-resistant dermatophytoses. J Am Acad Dermatol. 2021;85(6):1539-1543.
